| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Department of Cellular Biochemistry, Max-Planck-Institute for Biophysical Chemistry, D-37077 Goettingen, Germany
2 Children’s University Hospital, Pediatric Hematology and Oncology, 35392 Giessen, Germany
Correspondence: T.T. or A.B. E-mail ttuschl{at}mpibpc.gwdg.de; e-mail arndt.borkhardt{at}paediat.med.unigiessen.de
The ability of double-stranded RNA (dsRNA) to silence the expression of genes has been the focus of many studies in C. elegans and D. melanogaster. More recent research has looked for evidence of RNAi-mediated gene suppression in other model organisms. Now there is excitement that RNAi-based methodologies will allow for the rapid assessment and validation of proteins as potential drug targets. Additionally, we might now be standing on the edge of fundamentally new approaches to gene therapy as conducted through RNAi-mediated suppression of mutated genes.
RNA interference (RNAi) represents an evolutionarily conserved cellular defense for controlling the expression of foreign genes in most eukaryotes including humans. RNAi is triggered by double-stranded RNA (dsRNA) and causes sequence-specific mRNA degradation of single-stranded target RNAs homologous in response to dsRNA. The mediators of mRNA degradation are small interfering RNA duplexes (siRNAs), which are produced from long dsRNA by enzymatic cleavage in the cell. siRNAs are approximately twenty-one nucleotides in length, and have a base-paired structure characterized by two-nucleotide 3'-overhangs. Chemically synthesized siRNAs have become powerful reagents for genome-wide analysis of mammalian gene function in cultured somatic cells. Beyond their value for validation of gene function, siRNAs also hold great potential as gene-specific therapeutic agents.
This article has been cited by other articles:
|
|
 |
|
  L. Zhang, L. Gao, Y. Li, G. Lin, Y. Shao, K. Ji, H. Yu, J. Hu, D. V. Kalvakolanu, D. J. Kopecko, et al. Effects of Plasmid-Based Stat3-Specific Short Hairpin RNA and GRIM-19 on PC-3M Tumor Cell Growth Clin. Cancer Res., January 15, 2008; 14(2): 559 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Li, P. S. Pallan, M. A. Maier, K. G. Rajeev, S. L. Mathieu, C. Kreutz, Y. Fan, J. Sanghvi, R. Micura, E. Rozners, et al. Crystal structure, stability and in vitro RNAi activity of oligoribonucleotides containing the ribo-difluorotoluyl nucleotide: insights into substrate requirements by the human RISC Ago2 enzyme Nucleic Acids Res., October 8, 2007; 35(19): 6424 - 6438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Liu Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA Brief Funct Genomic Proteomic, July 31, 2007; (2007) elm015v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zhang, L. Gao, L. Zhao, B. Guo, K. Ji, Y. Tian, J. Wang, H. Yu, J. Hu, D. V. Kalvakolanu, et al. Intratumoral Delivery and Suppression of Prostate Tumor Growth by Attenuated Salmonella enterica serovar typhimurium Carrying Plasmid-Based Small Interfering RNAs Cancer Res., June 15, 2007; 67(12): 5859 - 5864. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Prechtel, N. M. Turza, A. A. Theodoridis, and A. Steinkasserer CD83 Knockdown in Monocyte-Derived Dendritic Cells by Small Interfering RNA Leads to a Diminished T Cell Stimulation J. Immunol., May 1, 2007; 178(9): 5454 - 5464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. van de Water, O. C. Boerman, A. C. Wouterse, J. G. P. Peters, F. G. M. Russel, and R. Masereeuw INTRAVENOUSLY ADMINISTERED SHORT INTERFERING RNA ACCUMULATES IN THE KIDNEY AND SELECTIVELY SUPPRESSES GENE FUNCTION IN RENAL PROXIMAL TUBULES Drug Metab. Dispos., August 1, 2006; 34(8): 1393 - 1397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rubin, T. C. Murphy, J. Rahnert, H. Song, M. S. Nanes, E. M. Greenfield, H. Jo, and X. Fan Mechanical Inhibition of RANKL Expression Is Regulated by H-Ras-GTPase J. Biol. Chem., January 20, 2006; 281(3): 1412 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Holen, S. E. Moe, J. G. Sorbo, T. J. Meza, O. P. Ottersen, and A. Klungland Tolerated wobble mutations in siRNAs decrease specificity, but can enhance activity in vivo Nucleic Acids Res., August 19, 2005; 33(15): 4704 - 4710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Liu, F. Bi, Y. Pan, L. Sun, Y. Xue, Y. Shi, X. Yao, Y. Zheng, and D. Fan Reversal of the Malignant Phenotype of Gastric Cancer Cells by Inhibition of RhoA Expression and Activity Clin. Cancer Res., September 15, 2004; 10(18): 6239 - 6247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Agrawal, P. V. N. Dasaradhi, A. Mohmmed, P. Malhotra, R. K. Bhatnagar, and S. K. Mukherjee RNA Interference: Biology, Mechanism, and Applications Microbiol. Mol. Biol. Rev., December 1, 2003; 67(4): 657 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Husken, F. Asselbergs, B. Kinzel, F. Natt, J. Weiler, P. Martin, R. Haner, and J. Hall mRNA fusion constructs serve in a general cell-based assay to profile oligonucleotide activity Nucleic Acids Res., September 1, 2003; 31(17): e102 - e102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Czauderna, M. Fechtner, S. Dames, H. Aygun, A. Klippel, G. J. Pronk, K. Giese, and J. Kaufmann Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells Nucleic Acids Res., June 1, 2003; 31(11): 2705 - 2716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Abdelrahim, R. Smith III, and S. Safe Aryl Hydrocarbon Receptor Gene Silencing with Small Inhibitory RNA Differentially Modulates Ah-Responsiveness in MCF-7 and HepG2 Cancer Cells Mol. Pharmacol., June 1, 2003; 63(6): 1373 - 1381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Amarzguioui, T. Holen, E. Babaie, and H. Prydz Tolerance for mutations and chemical modifications in a siRNA Nucleic Acids Res., January 15, 2003; 31(2): 589 - 595. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ASPET Journals | Pharmacological Reviews | Drug Metabolism and Disposition |
| Molecular Interventions | Molecular Pharmacology | J Pharmacology and Exp Therapeutics |
